ストックスクリーナーアプリを入手
3.35
1.18%
-0.04
前日終値:
$3.39
開ける：
$3.38
24時間の取引高:
544.15K
Relative Volume:
1.04
時価総額：
$304.80M
収益：
$114.70K
当期純損益:
$-26.49M
株価収益率:
-1.3582
EPS:
-2.4665
ネットキャッシュフロー:
$-53.17M
1週間 パフォーマンス:
-4.29%
1か月 パフォーマンス:
-7.46%
6か月 パフォーマンス:
-13.44%
1年 パフォーマンス:
+55.09%
1日の値動き範囲:
$3.25
$3.44
1週間の範囲:
$3.25
$3.565
52週間の値動き範囲:
$1.85
$5.15
Sab Biotherapeutics Inc Stock (SABS) Company Profile
Compare SABS vs VRTX, REGN, MRNA, ARGX, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SABS
Sab Biotherapeutics Inc
|
3.35 | 304.80M | 114.70K | -26.49M | -53.17M | -2.4665 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sab Biotherapeutics Inc Stock (SABS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-02 | 開始されました | Rodman & Renshaw | Buy |
| 2025-12-19 | 開始されました | Guggenheim | Buy |
| 2025-09-17 | 開始されました | Leerink Partners | Outperform |
| 2025-05-14 | 再開されました | H.C. Wainwright | Buy |
| 2024-10-09 | 開始されました | Craig Hallum | Buy |
| 2024-08-28 | 開始されました | Oppenheimer | Outperform |
| 2021-11-05 | 開始されました | Chardan Capital Markets | Buy |
すべてを表示
Sab Biotherapeutics Inc (SABS) 最新ニュース
SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes - GlobeNewswire
SAB Biotherapeutics, Inc.(NasdaqCM: SABS) added to S&P Global BMI Index - marketscreener.com
SAB BIO at Citi summit: trial progress and a bigger t1d bet By Investing.com - Investing.com South Africa
SAB BIO at Citi summit: trial progress and a bigger t1d bet - Investing.com India
SAB BIO to Participate in Upcoming Investor Conferences - Investing News Network
SAB Biotherapeutics Inc. (SABS) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
SAB Biotherapeutics Inc. Warrant (SABSW) Key Financial Ratios – Valuation, Profitability & More - Value Research
SAB (SABSW) Market: Ends Higher by 13.58% at $0.03 in the Current Update; Range Check - vinanet.vn
SAB (SABSW) Session: Moves 7.02% Down to $0.03 at the Close; Boundary Watch - vinanet.vn
SAB (SABS) Today: Posts a 2.16% Gain to $3.78 in the Current Update; Price Setup: the Current Price Sits Inside the Supplied Technical Range in the Latest SessionLiquidity Sweep - vinanet.vn
SAB (SABSW) Latest: Falls 14.29% to $0.02 in the Current Update; Level Watch - vinanet.vn
Price to earnings forward of SAB Biotherapeutics, Inc. – BOATS:SABSW - TradingView
Balyasny Asset Management L.P. Expands Stake in SAB Biotherapeutics Inc (SABS) - GuruFocus
SAB (SABS) Earnings Update: EPS Prints Above Forecast in the Current Update; Market Move: Shares Move Lower 0.26% in the Latest SessionROE Trend Analysis - vinanet.vn
SAB Biotherapeutics (SABS) Slips 1.33% to $3.70 as Support Level Comes into FocusCash Flow Strong Stocks - vinanet.vn
Perceptive Advisors discloses 7.3% SAB Biotherapeutics (SABS) stake via Master Fund - Stock Titan
Caligan Partners (SABS) discloses 7.97M SAB Biotherapeutics shares in amended 13G - Stock Titan
Commodore Capital discloses 8.95M-share position in SAB Biotherapeutics (SABS) - Stock Titan
Vivo funds (SABS) report capped 9.99% stakes via preferred stock and warrants - Stock Titan
Woodline Partners (SABS) discloses 5.46M-share beneficial stake in SAB Biotherapeutics - Stock Titan
Balyasny Asset Management (SABS) discloses 7.2M-share SAB Biotherapeutics position capped at 9.99% - Stock Titan
Adage discloses 8.38% SAB Biotherapeutics (SABS) ownership in Schedule 13G - Stock Titan
SAB Biotherapeutics, Inc. (NASDAQ:SABS) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
RA Capital group discloses 9.9% SAB Biotherapeutics (SABS) stake capped by ownership blockers - Stock Titan
What is HC Wainwright's Estimate for SABS Q3 Earnings? - MarketBeat
Q3 EPS Estimate for SAB Biotherapeutics Boosted by Analyst - MarketBeat
SAB Biotherapeutics (NASDAQ:SABS) Upgraded by Wall Street Zen to "Sell" Rating - MarketBeat
H.C. Wainwright Maintains SAB Biotherapeutics(SABS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
SAB Biotherapeutics Q2 Earnings Call Highlights - MarketBeat
SABS FY2030 EPS Boosted by Brookline Capital Markets - marketbeat.com
SAB Biotherapeutics (SABS) Rises 1.43% to $3.9 — Key Resistance at $4.09 in FocusIntraday Trade Ideas - careplusvn.com
SAB Biotherapeutics (NASDAQ:SABS) Posts Earnings Results, Hits Estimates - MarketBeat
SAB Biotherapeutics Inc (SABS) (Q2 2026) Earnings Call Highlights: Advancing SAB142 with Strong ... - Yahoo Finance
Earnings call transcript: SAB Bio posts wider Q2 2026 loss as trial momentum builds - Investing.com Nigeria
SAB Biotherapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
SAB Biotherapeutics, Inc. Q2 2026: Net loss $(22.5M), EPS $(0.28) — 10-Q Summary - TradingView
SAB Biotherapeutics (NASDAQ: SABS) posts Q2 loss after March 2026 stock offering - Stock Titan
SAB BIO Reports Q2 2026 Results, Expands SAB-142 Type 1 Diabetes Trials and Secures Breakthrough T1D Grant for PRISE-hATG Study - Quiver Quantitative
SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - The Manila Times
Press Release: SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights - Moomoo
S.D.-born biotech advances potential Type 1 diabetes therapy through global trial - siouxfalls.business
SAB Biotherapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
SAB Biotherapeutics Inc expected to post a loss of 29 cents a shareEarnings Preview - TradingView
SABS Q1 2026 Earnings: Wider-than-Expected Loss Highlights Clinical-Stage Development CostsEarnings Miss Streak - vinanet.vn
SAB Biotherapeutics (NASDAQ:SABS) Downgraded by Wall Street Zen to Strong Sell - MarketBeat
SAB Biotherapeutics Warrant (SABSW) Jumps 40.85% to $0.02 Amid Renewed Speculative InterestTriple EMA - careplusvn.com
SABSW Edges Higher in Thin Trading: Warrant Holds at $0.01Time Weighted Price - careplusvn.com
SAB Biotherapeutics, Inc. Revenue Breakdown – NASDAQ:SABS - TradingView
SABS|SAB Biotherapeutics Inc|Price:3.435|Chg%:-0.075 - TradingKey
SAB Biotherapeutics Inc (SABS) Institutional Confidence - TradingKey
SAB Biotherapeutics Inc (SABS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Sab Biotherapeutics Inc (SABS) 財務データ
収益
当期純利益
現金流量
EPS
Sab Biotherapeutics Inc (SABS) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Sessa Capital (Master), L.P. | Director |
Sep 29 '25 |
Option Exercise |
1.75 |
1,740,000 |
3,045,000 |
2,198,457 |
1.11%
1.87%
大文字化:
|
ボリューム (24 時間):